PVCT 10% Owner Pershing Edward Converts Note to Preferred

What Happened
Pershing Edward, reported as a 10% owner of Provectus Biopharmaceuticals, converted a 2025 unsecured convertible promissory note into 13,216 shares of the company's Series D‑1 Convertible Preferred Stock. The Form 4 reports the derivative acquisition at $0.00 (conversion of debt), but the note conversion price per the filing was $2.862 per Series D‑1 share — implying roughly $37,800 of principal/interest was converted. This is a conversion of debt to preferred stock (transaction code M), not an open‑market buy or sale.

Key Details

• Transaction date: 2026-09-18 (filed 2026-09-18 — appears timely).
• Reported acquisition: 13,216 shares of Series D‑1 Convertible Preferred Stock at $0.00 (derivative conversion).
• Implied conversion terms: 2025 Note converted at $2.862 per Series D‑1 share (13,216 × $2.862 ≈ $37,824).
• Conversion mechanics: Each Series D‑1 preferred share is convertible into 10 shares of common stock (so 13,216 preferred = 132,160 potential common shares).
• Automatic conversion: Series D‑1 will automatically convert into common stock on December 31, 2028 unless earlier converted.
• Footnote context: The 2025 Note could have been voluntarily converted earlier; it automatically converted 12 months after issuance per the 2025 financing terms.
• Shares owned after transaction: not specified in the excerpt of the filing provided.
• Insider type: Reporting person is a 10% owner (institutional/large holder), not necessarily an executive — conversions of financing instruments are routine corporate-finance events.

Context
This was a debt-to-preferred conversion (derivative conversion), not a market purchase or sale. For retail investors: conversions like this reflect financing/structural changes in cap table rather than a direct bullish or bearish trading signal by company insiders. The preferred shares are convertible into common stock later (10:1 ratio), which could affect share count if and when conversion occurs.